Back to Interventions
Substance / Medication

Tolbutamide

SNOMED 373481003UMLS C0040374

Overview

Active Ingredient
tolbutamide
RxNorm CUI
10635

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Diabetes mellitus type II

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Creatinine

LOINC 2160-0

secondary

Sodium

LOINC 2951-2

secondary

Glucose

LOINC 2345-7

primary

Hemoglobin A1c

LOINC 4549-2

primary

Clinical Trials

2 trials linked to this intervention

2
Total Trials
0
Recruiting
0
With Results

Recent Trials

Evaluation of CYP450 Activities in Diabetic Patients vs. Non-diabetic Subjects

NCT02291666Phase 4Completed73 enrolled

A Pharmacokinetic Evaluation of Metformin in Relation to the Polymorphism A270S in Healthy Caucasian Volunteers

NCT01237522Phase 4Completed50 enrolled
View all 2 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:
Evaluation of the pharmacokinetic interaction between ticagrelor and tolbutamide, a cytochrome P450 2C9 substrate, in healthy volunteers.
Teng Renli, Mitchell Patrick, Butler Kathleen · Int J Clin Pharmacol Ther · 2013
PMID: 23380426RCT
Microdose pharmacogenetic study of ¹⁴C-tolbutamide in healthy subjects with accelerator mass spectrometry to examine the effects of CYP2C9∗3 on its pharmacokinetics and metabolism.
Ikeda Toshihiko, Aoyama Shinsuke, Tozuka Zenzaburo et al. · Eur J Pharm Sci · 2013
PMID: 23727057RCT
Evaluation of a six-probe cocktail (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam, and digoxin) approach to estimate hepatic drug detoxification capability and dosage requirements after a single oral dosing in healthy Chinese volunteers.
Koo Seok Hwee, Soon Gaik Hong, Pruvost Alain et al. · Naunyn Schmiedebergs Arch Pharmacol · 2022
PMID: 35394133Trial
Evaluation of vatiquinone drug-drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjects.
Murase Katsuyuki, Lee Lucy, Ma Jiyuan et al. · Eur J Clin Pharmacol · 2022
PMID: 36166059Trial
Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects.
Wang Jing, Zhang Zhi-Yi, Lu Sharon et al. · Support Care Cancer · 2019
PMID: 30084103TrialFull text (PMC)
Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers.
Uchida Shinya, Yamada Hiroshi, Li Xiao Dong et al. · J Clin Pharmacol · 2006
PMID: 17050793Trial
No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract.
Arold Gerhard, Donath Frank, Maurer Agathe et al. · Planta Med · 2005
PMID: 15856409Trial
Is acarbose equivalent to tolbutamide as first treatment for newly diagnosed type 2 diabetes in general practice? A randomised controlled trial.
van de Laar Floris A, Lucassen Peter L B J, Kemp Jaco et al. · Diabetes Res Clin Pract · 2004
PMID: 14693413Trial
Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans.
Lee Craig R, Pieper John A, Frye Reginald F et al. · J Clin Pharmacol · 2003
PMID: 12520632Trial
Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.
Shon Ji-Hong, Yoon Young-Ran, Kim Kyoung-Ah et al. · Pharmacogenetics · 2002
PMID: 11875365Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Family Medicine Physician

Family Medicine

NUCC 207Q00000X
Internal Medicine Physician

Internal Medicine

NUCC 207R00000X
Endocrinology, Diabetes & Metabolism Physician

Internal Medicine — Endocrinology, Diabetes & Metabolism

NUCC 207RE0101X
Find a Provider

Health Goals

Goals connected through associated conditions

Monitor Blood SugarOptimize Metabolic Function

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tolbutamide (substance)
SNOMED CT
373481003
UMLS CUI
C0040374
RxNorm CUI
10635

Clinical Data

This intervention maps to 10 entities in the Ltrl knowledge graph.

1
Conditions
4
Biomarkers
3
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.